论文部分内容阅读
目的观察吉西他滨联合长春瑞滨方案治疗蒽环类和紫杉类均耐药的晚期乳腺癌的近期临床疗效和不良反应。方法吉西他滨联合长春瑞滨治疗蒽环类和紫杉类均耐药的晚期乳腺癌患者29例,21～28 d为1个周期,至少连续2周期化疗后评价临床疗效和不良反应。结果完全缓解0例、部分缓解11例、稳定12例、进展6例;有效率37.9%,临床获益率55.2%;主要不良反应为骨髓抑制及胃肠道反应。结论吉西他滨联合长春瑞滨方案治疗蒽环类和紫杉类均耐药的晚期乳腺癌有较好的疗效,不良反应可耐受,可考虑作为解救方案。
Objective To observe the short-term clinical efficacy and side effects of gemcitabine combined with vinorelbine in the treatment of advanced breast cancer resistant to both anthracyclines and taxanes. Methods 29 cases of advanced breast cancer patients treated with gemcitabine combined with vinorelbine for both anthracyclines and taxanes were treated with gemcitabine combined with vinorelbine for 21 to 28 days. The clinical efficacy and adverse reactions were evaluated after at least two consecutive cycles of chemotherapy. The results of complete remission in 0 cases, partial remission in 11 cases, stable in 12 cases, progress in 6 cases; effective rate was 37.9%, clinical benefit rate was 55.2%; the main adverse reactions were myelosuppression and gastrointestinal reactions. Conclusion Gemcitabine combined with vinorelbine regimen has good efficacy in the treatment of advanced breast cancer with anthracycline and taxane resistant. The adverse reactions are tolerable and may be considered as a rescue plan.